Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07265807 + sasanlimab + axitinib
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
A combination therapy of three agents: **PF-07265807**, a small-molecule inhibitor of MERTK and AXL receptor tyrosine kinases, **sasanlimab**, a monoclonal antibody targeting PD-1 (programmed cell death protein 1), and **axitinib**, a small-molecule inhibitor of vascular endothelial growth factor receptors (VEGFR). This triplet is under investigation for advanced or metastatic solid tumors, especially clear cell renal cell carcinoma. PF-07265807 is designed to inhibit TAM kinases (AXL and MERTK), potentially lowering the immune activation threshold and enhancing antitumor immunity. Sasanlimab blocks PD-1, releasing the immune checkpoint brake on T-cells. Axitinib inhibits VEGFR to disrupt tumor angiogenesis. The combination aims to simultaneously target tumor immune evasion and angiogenesis, with clinical studies focusing on safety, tolerability, pharmacokinetics, and preliminary efficacy in advanced cancers, primarily renal cell carcinoma[1][3].
- Other names
- PF-07265807 + sasanlimab + axitinib
02
Targets
AXL (AXL receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on PF-07265807 + sasanlimab + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07265807 + sasanlimab + axitinib.